文献速递腹部泌尿生殖CT

胰腺神经内分泌肿瘤的增强MDCT:与组织学表现的相关性及鉴别肿瘤分级的诊断效能

Contrast-enhanced MDCT in patients with pancreatic neuroendocrine tumours: correlation with histological findings and diagnostic performance in differentiation between tumour grades.
PubMed 文献 · Clin Radiol · 2016-11-24

本研究纳入39例经组织学确诊的胰腺神经内分泌肿瘤患者,术前均行增强MDCT,其中G1级19例、G2级20例。结果显示动脉期强化比均值G1为1.53±0.45、G2为1.01±0.33(p=0.0003),且与瘤内微血管密度相关(r=0.55,p=0.0002);肿瘤晚期强化与G2显著相关。肿瘤大小>20mm、动脉强化比<1.1和晚期强化诊断G2的准确率分别为74.4%、79.5%和74.4%,至少满足两条标准组合的准确率为82%。

要点

  • 动脉期强化比G1为1.53±0.45、G2为1.01±0.33(p=0.0003),与瘤内微血管密度相关(r=0.55,p=0.0002)。
  • 肿瘤大小>20mm、动脉强化比<1.1、晚期强化单独诊断G2准确率分别为74.4%、79.5%、74.4%。
  • 至少满足上述两条标准组合诊断G2准确率为82%,所提诊断算法预测分级的观察者间一致性高(k=0.82)。

核心结论

  • 增强MDCT特征与组织学表现相关,可在术前检查中区分G1与G2级胰腺神经内分泌肿瘤。

研究设计与样本

  • 纳入39例经组织学确诊的胰腺神经内分泌肿瘤患者,术前均行增强MDCT,其中G1级19例、G2级20例;回顾组织病理切片评估瘤内微血管密度与肿瘤间质含量,CT图像分析包括肿瘤大小、边缘、钙化、均匀性、强化模式、肿瘤绝对与相对强化、囊性变、胰管扩张及区域和远处转移,并评估各MDCT征象及其组合预测肿瘤分级的诊断能力。

关键影像表现/征象

  • 动脉期强化比均值G1为1.53±0.45、G2为1.01±0.33(p=0.0003),且与瘤内微血管密度相关(r=0.55,p=0.0002)。
  • 肿瘤间质百分比与影像表现无相关性。
  • 肿瘤晚期强化(静脉期观察到的峰值衰减)与G2显著相关。

诊断标准与关键数值

  • 肿瘤大小>20mm诊断G2的准确率为74.4%。
  • 动脉强化比<1.1诊断G2的准确率为79.5%。
  • 晚期强化诊断G2的准确率为74.4%。
  • 至少满足上述两条标准组合诊断G2的准确率为82%。
  • 基于上述结果提出的诊断算法预测肿瘤分级的观察者间一致性高(k=0.82)。

临床应用与阅片要点

  • 阅片时可评估肿瘤大小、动脉期强化比及晚期强化(静脉期峰值衰减)以辅助区分G1与G2级胰腺神经内分泌肿瘤。
  • 至少满足肿瘤大小>20mm、动脉强化比<1.1、晚期强化中两条标准时,诊断G2的准确率为82%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

AIM: To identify the multidetector computed tomography (MDCT) features of pancreatic neuroendocrine tumours (pNETs), which correlate with tumour histology and enable preoperative grading.

MATERIALS AND METHODS: Thirty-nine patients with histologically confirmed pNET who underwent preoperative contrast-enhanced MDCT were included in this study. Nineteen tumours were classified as Grade 1 (G1) and 20 as Grade 2 (G2). Histopathology slides were reviewed to assess the intratumoural microvascular density (MVD) and the amount of tumour stroma. Computed tomography (CT) image analysis included tumour size, margin delineation, calcifications, homogeneity, contrast enhancement (CE) pattern, tumour absolute and relative enhancement, presence of cystic changes, pancreatic duct dilatation, regional and distant metastases. The diagnostic ability to predict tumour grade was measured for each MDCT finding and their combinations.

RESULTS: The mean arterial enhancement ratio had a mean±standard deviation of 1.53±0.45 in G1 and 1.01±0.33 in G2 pNETs (p=0.0003) and correlated with intratumoural microvascular density (MVD; r=0.55, p=0.0002). Tissue stroma percentage did not correlate with imaging findings. Late CE of the tumour (the peak attenuation observed in the venous phase) was significantly associated with G2. Tumour size >20 mm, arterial enhancement ratio <1.1, and late CE showed 74.4%, 79.5%, and 74.4% accuracy, respectively, in diagnosing G2 tumours, while the accuracy of at least two of these criteria used in combination was 82%. Based on these results, a diagnostic algorithm was proposed, which showed high interobserver agreement (k=0.82) in the prediction of tumour grade.

CONCLUSION: Contrast-enhanced MDCT features correlate with histological findings and enable the differentiation between G1 and G2 pNETs during preoperative examination.

来源:Clin Radiol,查看原文。版权归原作者所有。

引用

  1. Belousova E, Karmazanovsky G, Kriger A, et al. Contrast-enhanced MDCT in patients with pancreatic neuroendocrine tumours: correlation with histological findings and diagnostic performance in differentiation between tumour grades. Clin Radiol. 2016. PMID: 27890421. doi:10.1016/j.crad.2016.10.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。